Avecho Clears Final Hurdle Before Phase III CBD Sleep Trial Interim Readout
Avecho hits final clinical milestone ahead of Phase III insomnia interim analysis
Avecho Biotechnology Limited (ASX: AVE) has announced that the last patient required for the planned interim analysis of its pivotal Phase III Insomnia Trial has successfully completed the treatment phase. In total, 244 participants have been recruited and completed treatment, randomised across three groups receiving nightly doses of either 150mg CBD, 75mg CBD, or placebo in a TPM-enhanced capsule. Interim analysis results remain on track for late June 2026.
The upcoming analysis represents a significant inflection point for the programme, with three material outcomes expected:
- First indication of the product’s efficacy profile
- Inform total participant numbers required for the final study population
- Support the progression of ongoing licensing discussions, including commercialisation opportunities outside Australia
CEO Dr Paul Gavin will host a live investor update webinar at 11am AEST on Monday 25 May 2026 ahead of the interim readout.
When big ASX news breaks, our subscribers know first
What is TPM®-enhanced CBD and why does it matter for insomnia?
TPM® (Tocopheryl Phosphate Mixture) is a proprietary, patented drug delivery system derived from Vitamin E. It is designed to enhance the solubility and oral absorption of drugs and nutrients, including CBD. Avecho’s lead product is a CBD TPM soft-gel capsule, with the TPM® component specifically engineered to increase the bioavailability of CBD when taken orally, a key differentiator versus standard CBD formulations where absorption is typically inconsistent.
Insomnia is clinically defined as dissatisfaction with sleep quantity or quality, associated with difficulty initiating sleep, difficulty maintaining sleep, or the inability to return to sleep after waking. Chronic insomnia, the most prevalent form, is characterised by symptoms occurring at least three nights per week for at least three months. Its consequences include daytime sleepiness, impaired memory, and reduced concentration.
The market opportunity for an approved treatment is substantial. Approximately 10–30% of the global population experience insomnia symptoms, with up to 237 million people affected worldwide. In Australia, as many as ~60% of the population report at least some symptoms, with the total cost to the Australian economy estimated at A$19.1 billion.
Critically, 2020 regulatory changes established a TGA over-the-counter (OTC) CBD registration pathway permitting pharmacy sales of CBD products without a prescription, provided appropriate approvals are obtained. OTC status is commercially significant as it removes prescription barriers and opens direct consumer access through pharmacy retail channels.
| Market | Market Size | Source Metric | Relevance to Avecho |
|---|---|---|---|
| Australian OTC CBD market | US$125M+ per year | Fresh Leaf Analytics | TGA OTC pathway target |
| Global insomnia market | US$5.22 billion (2024) | Cited in announcement | Subsequent overseas regulatory submissions |
| Global sleep economy | US$950 billion by 2032 | Yahoo Finance | Long-term market backdrop |
| People affected by insomnia globally | Up to 237 million | Global population data | Scale of unmet need |
Commercial foundation already in place as trial reaches inflection point
Avecho has already secured meaningful commercial validation ahead of the interim readout. In 2025, the company licensed the commercialisation rights for Australia to Sandoz AG. Under the terms of the Sandoz AG agreement, Avecho received an upfront payment of US$3 million, is eligible for up to US$16 million in development and commercial milestone payments, and will receive tiered royalties of 14–19% on net sales.
The interim analysis now carries direct implications for the next phase of commercial negotiations. A positive outcome has the potential to strengthen Avecho’s negotiating position as it pursues commercialisation opportunities beyond the Australian market.
CEO Dr Paul Gavin
“With Sandoz already established as our Australian commercial partner, a positive interim analysis outcome has the potential to materially de-risk the program and strengthen Avecho’s position in discussions relating to commercialisation opportunities outside Australia.”
The trial itself has been structured to support multiple regulatory pathways. It is a multi-centre, randomised, double-blind, placebo-controlled study designed to meet the requirements of the TGA, the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA). This multi-jurisdictional design means the data generated could support regulatory submissions well beyond Australia, directly underpinning the international licensing discussions referenced by management.
The next major ASX story will hit our subscribers first
What comes next: June interim analysis and the pathway to TGA registration
With the treatment phase now complete, the clinical database will be locked and the data cleaned before being passed to an independent blinded statistics team. That team will conduct the interim analysis and provide results to the independent Data Monitoring Board (DMB), which will review the outcomes and issue recommendations in accordance with the study protocol. Results are on track for late June 2026.
A successful Phase III trial represents Avecho’s final clinical step before a TGA submission for pharmaceutical registration of the CBD TPM soft-gel capsule for the management of insomnia. The company is positioned to be the first to capitalise on the TGA’s unique over-the-counter (OTC) CBD registration pathway, with no other Phase III CBD trials in Australia having succeeded to date.
The key upcoming milestones for investors to monitor are:
- Clinical database lock and data clean (underway)
- Independent statistical analysis (blinded team)
- DMB review and recommendations
- Interim analysis results — late June 2026
- Investor webinar — Monday 25 May 2026, 11am AEST
Investor Webinar — Register Now
CEO Dr Paul Gavin will host a live update ahead of the Phase III interim analysis.
Date: Monday 25 May 2026
Time: 11am AEST
Register: https://us02web.zoom.us/webinar/register/WNun03u7nDS9GfsKlhqlQlwA recording will be available at the registration link shortly after the live session concludes. The replay will also be accessible via the company’s website and social media channels. Questions may be submitted during the session or emailed in advance to matt@nwrcommunications.com.au.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market on announcements just like this one. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.